SEC16B

Across TCGA pan-cancer cohorts, SEC16B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SEC16B data layer compared with 19 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SEC16B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SEC16B expression acts as an unfavorable survival marker.

PDAC, GBM, and LSCC are the cancer types where SEC16B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	IV	0.231	0.973	.024	9	view →
GBM	DFS	Tertile	All	0.235	0.433	.016	8	view →
LSCC	DFS	Quartile	All	0.484	0.854	.032	4	view →
LUAD	DFS	Tertile	All	0.496	0.711	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SEC16B–PDAC (OS)

Open the PDAC breakdown →